Table 2 Patient Consensus on OMERACT TJR Clinical Trial Core Areas/Domains
OMERACT PRP (n = 31) Median [IQR] | SVPH Cohort (n = 118a) Median [IQR] | p-value (Mann–Whitney test) | |
|---|---|---|---|
Core Domains to be reported in every TJR clinical trial | |||
Joint Pain | 8 [8, 9] | 9 [8, 9] | 0.75 |
Function or functional ability (ability to function in society, work; work productivity, employability; disability; work disability) | 9 [8, 9] | 9 [8, 9] | 0.31 |
Patient Satisfaction (satisfaction with the outcome, satisfaction with the procedure) | 8 [8, 9] | 8 [7, 9] | 0.86 |
Revision surgery (including reoperation) | 7 [7, 8] | 7 [5, 9] | 0.97 |
Adverse events (total and specific) | 8 [7, 9] | 8 [6, 9] | 0.84 |
Death | 9 [6, 9] | 9 [4, 9] | 0.70 |
Additional domains for consideration for reporting in TJR clinical trials | |||
Patient Participation | 8 [6.5, 8] | 7 [6, 9] | 0.98 |
Cost | 6 [5, 7] | 7 [6, 8] | 0.005 |